Boehringer Ingelheim vs. Sun Pharma: Consent Judgment Resolves Empagliflozin Patent Battle

Case Overview

In a significant resolution for the pharmaceutical patent litigation landscape, Boehringer Ingelheim and Sun Pharmaceutical Industries reached a consent judgment on July 30, 2025, in the U.S. District Court for the District of Delaware. The negotiated outcome confirmed that eleven Boehringer patents covering empagliflozin-based diabetes therapies—including blockbuster brands Jardiance, Synjardy, Glyxambi, and Trijardy XR—are valid, enforceable, and infringed by Sun’s generic ANDA products.

The Parties

The Patents at Issue

This landmark case involved eleven patents covering core empagliflozin compound, formulation, combination therapy, and method-of-treatment claims:

• • U.S. Patent No. 7,713,938 — empagliflozin compound
• • U.S. Patent No. 8,551,957 — formulation claims
• • U.S. Patent No. 9,949,998 — therapeutic use
• • U.S. Patent No. 10,258,637 — combination therapy
• • U.S. Patent No. 9,155,705 — dosage forms
• • U.S. Patent No. 9,415,016 — combination formulations
• • U.S. Patent No. 10,022,379 — treatment methods
• • U.S. Patent No. 10,406,172 — patient population claims
• • U.S. Patent No. 10,596,120 — extended-release combinations
• • U.S. Patent No. 7,579,449 — linagliptin compound
• • U.S. Patent No. 11,090,323 — later-filed combination patent

The Verdict & Legal Analysis

On July 30, 2025, the Delaware District Court entered a Consent Judgment stipulated by both parties. The judgment declared all eleven Boehringer patents—the ‘938, ‘957, ‘998, ‘637, ‘705, ‘016, ‘379, ‘172, ‘120, ‘449, and ‘323 patents—valid, enforceable, and infringed by Sun’s ANDA products. No damages figure was publicly disclosed, consistent with typical negotiated Hatch-Waxman resolutions where the primary remedy is injunctive in nature.

Injunctive Relief & Preserved Rights

Sun is permanently enjoined from making, using, selling, offering for sale, importing, or distributing the Sun ANDA Products in the United States until expiration of all eleven patents, including any patent term extensions, patent term adjustments, or pediatric exclusivity periods. The judgment also provides Boehringer the right to petition for court modification if additional regulatory exclusivities are later granted—a forward-looking protective provision rarely articulated so explicitly in consent judgments.

A critically important carve-out: Sun retains the right to challenge the validity, enforceability, and infringement of all eleven patents in connection with products other than those covered by the five named ANDAs. This preserves Sun’s future litigation optionality without undermining the present resolution.

The consent judgment’s explicit patent validity acknowledgment—rather than a simple dismissal—carries meaningful strategic weight. By stipulating to validity and infringement rather than merely dismissing claims, Boehringer secured a stronger enforcement record that could inform future ANDA challenges by other generic manufacturers.